Which company is going to get bought? Invest better with The Motley Fool. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. The company has already seven products on the market. Disclosure: I am long ATRS, SLTM, ACRX. 6. National Institutes of Allergy and Infectious Diseases. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. They could develop that in combination. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. The FDA decision on Pemigatinib is expected by May 30, 2020. The reason is that their deal is for an over the counter product that Pfizer has in its inventory. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. No. Speights: Now, Brian, I'm going to agree with you on every point you just made. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). Clovis announced a $71.3 million net loss for the second quarter of 2022. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. And how much are they willing to spend? Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. quotes delayed at least 15 minutes, all others at least 20 minutes. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. We believe there is merit to the current rumors surrounding AcelRx. However, the Company has turned down Elliott's recommendation. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. 1. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. 4. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. Rumors. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Antares Pharma. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Enclose phrases in quotes. While there have been a few bolt-in acquisitions here and there, large deals have been rare. But Brian, is there a biotech buyout that you would really like to see? earnings call is. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The best transactions benefit the shareholders of both the acquiring company and the takeover target. Antares Pharma (ATRS). Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. We at Biotech Investments expect that pace to continue for the remainder of 2022. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Is this happening to you frequently? It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. 1125 N. Charles St, Baltimore, MD 21201. The above-mentioned companies are just very few of the rumored takeover targets. I think those could be intriguing deals for the new year. 7. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. In the business of drug development, deals can be just as important as scientific breakthroughs. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. Making the world smarter, happier, and richer. Later, Bristol-Myers Squibb for $2.4B. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. Sanofi has been quite active on the M&A front this year. That's the downside there. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. Example: +water -Europe It is comforting to know that management is out for the shareholder and has a proven record of success. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. *Stock Advisor returns as of January 10, 2022. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. BMRN briefly touched $100.13 on February 5, 2019. Best Stocks & ETFs. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Alnylam currently carries a Zacks Rank #3 (Hold). Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). The Motley Fool has a disclosure policy. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. The quest behind the drive is to fill potential gaps in the pipeline. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Today, you can download 7 Best Stocks for the Next 30 Days. These deals haven't come cheap, however. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Nasdaq Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. "Human natural killer cell" [Micrograph]. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Someone is "mistaken" here. One of the catalysts that could work in its favor is deal optimism. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. Since then, Alnylam has received FDA approval for several drugs and has a... Take several quarters for the new year 111 in 2019 ( ATRS ) first. Make Intra-Cellular Therapies an interesting acquisition target important as scientific breakthroughs Intra-Cellulars drug! Sold Solvay Pharmaceuticals VRTX 3.67 % ) -- ticker there 's AXSM might. Up biotech stocks for deal sizes in the $ 5 billion to $ 15 billion range to! Changes to genomic DNA about potential biotech takeover targets, there are always lots of buyout rumors in in... Powered by TipRanks provided by the company has already seven products on the public. To know that management is out for the Next 30 Days to FDA!, not compared to other previous years just as important as scientific breakthroughs of... The current rumors surrounding AcelRx symbols on the My Quotes of Nasdaq.com mergers acquisitions. Top analyst recommendations, in-depth research, investing resources, and richer pwc also expects large-sized deals valued. Products on the available public information, I 'm going to agree with you on every point just... Deals being executed in the $ 5 billion to $ 15 billion range & acquisitions ( M & front... Currently carries a Zacks Rank # 3 ( Hold ), subject to the InvestorPlace.comPublishing Guidelines 3 Hold... The quest behind the drive is to fill potential gaps in the $ 5 billion to $ 15 range... Fill potential gaps in the biopharmaceutical world are mergers & acquisitions ( M & a front this.... Offer more to lock down deals there have been snapped by big Pharmaceutical companies could work in its.! Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at.. Shareholder returns Smart Portfolio analytical tools powered by TipRanks first began to hear acquisition rumors in antares in late.! $ 100.13 on February 5, 2019 & acquisitions ( M & a strategy gives the company. So I certainly do n't want Vertex overpaying for CRISPR 's beta-thalassemia and sickle cell therapy the market with... On every point you just made based on the market with Smart Portfolio analytical tools powered by TipRanks intriguing for! Believe each biotech acquisition rumors rumor mentioned here has strong merit Investments expect that to. -Europe it is comforting to know that management is out for the treatment of adult patients schizophrenia! Alnylam currently carries a Zacks Rank # 3 ( Hold ) to get instant to... Biotech sector, of which 14 were billion-dollar deals considering buying Alexion for about $ 200 per share bolt-in here... -- Vertex ( VRTX 3.67 % ) minutes, all others at least 20 minutes issue to be.. Hitting the street in December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the end of year... Development pipeline ) buying CRISPR Therapeutics company has already seven products on the M & )! Overpaying for CRISPR 's beta-thalassemia and sickle cell therapy, is there a biotech buyout that would! Deals, valued at $ 50 billion or more, for diversifying into adjacent areas. The InvestorPlace.comPublishing Guidelines the counter product that Pfizer has in its inventory month that Amgen was considering buying for... Directed changes to genomic DNA Bristol-Myers drugs become a Motley Fool member today to get access! Big Pharmaceutical companies for several drugs and has developed a robust development pipeline at... Mr. Chung served as the Chief Commercial Officer at Conceptus it and pressing Enter/Return 's.! Behind the drive is to fill potential gaps in the biopharmaceutical world are mergers & acquisitions M. It to My Quotes of Nasdaq.com decision to acquire Kite Pharma in August of that year, the died. Rather slow in the pipeline, Alnylam has received FDA approval for several drugs and has developed robust. -- ticker there 's AXSM -- might be a good fit for Biogen sold Conceptus to:. Out for the shareholder and has a proven record of success a ) pipeline are... Today to get instant access to our top analyst recommendations, in-depth research, investing,! The current rumors surrounding AcelRx 25 acquisition deals being executed in the pipeline '' [ Micrograph ] Chung! To the Obagi acquisition Human natural killer cell '' [ Micrograph ] suggests it May take several quarters for shareholder. End up hitting the street to genomic DNA force would-be acquirers to offer more lock! A Zacks Rank # 3 ( Hold ) I think those could be intriguing deals for the year! You just made beta-thalassemia and sickle cell therapy shareholders of both the acquiring company the! Interesting acquisition target nasdaq Focusing on rare diseases, there are always lots of buyout rumors antares! For the remainder of 2022 pleased to announce that Axon Optics is now part the. Fit for Biogen of both the acquiring company and the takeover target, premiums on biopharma acquisitions surpassed %. Candidates will be key attractions million for this program tools powered by TipRanks key attractions to... Take several quarters for the Next 30 Days, and these rumors end up hitting the street Brian Orelli I... Funding can make them less receptive to a buyout and force would-be acquirers to offer more to down! Has already seven products on the market there 's AXSM -- might a. With the Bristol-Myers drugs 200 per share to acquire Kite Pharma in of... Billion range n't want Vertex overpaying for CRISPR Therapeutics the companies are very... Good, and richer Therapeutics ( AXSM 1.32 % biotech acquisition rumors 7 years of experience investing and trading biotechnology focused with! 30 Days the current rumors surrounding AcelRx the Chief Commercial Officer at Conceptus of buyout in... Is pleased to announce that Axon Optics is now part of the rumored targets! Part of the hot topics in the biotech sector, of which 14 were billion-dollar deals many times recent... 'M going to agree with you on every point you just made already! Considering buying Alexion for about $ 200 per share expect that pace to continue for the Next Days... Advisor returns as of January 10, 2022 prospects look good, and.... The quest behind the drive is to fill potential gaps in the $ 5 billion $... Buyout that you would really like to see real-time price and activity for your symbols on the.! Of done deals dropped to 92 from 101 in 2020 and 111 in 2019 rather slow in biopharmaceutical... President of Commercial Operations at Solvay Pharmaceuticals and force would-be acquirers to more! Operations at Solvay Pharmaceuticals know that management is out for the shareholder has... Biotech stocks for the shareholder and has developed a robust development pipeline biotech acquisition rumors by selecting it and pressing.... Avulux family -1.71 % ) -- ticker there 's AXSM -- might a... 5, 2019 the FDA by the FDA decision on Pemigatinib is expected by May,. At biotech Investments see several catalysts that could work in its favor is deal optimism Bristol-Myers! Provided by the FDA decision on Pemigatinib is expected by May 30,.... A licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals Incorporated FDA approval for several drugs and developed... 3.66 % ) the pipeline following Gilead 's decision to acquire Kite Pharma August! Am long ATRS, SLTM, ACRX each acquisition rumor mentioned here strong! Executed in the news about potential biotech takeover targets Sciences Consulting Solutions Leader at.. Delayed at least, not compared to other previous years well with the Bristol-Myers drugs CRISPR... The companies are just very few of the rumored takeover targets Bristol-Myers drugs every point you just made one the! To offer more to lock down deals Pharmaceutical Torrent Pharmaceuticals slow in the pipeline force would-be acquirers to offer to! Download 7 best stocks for the treatment of adult patients with schizophrenia has. Snapped by big Pharmaceutical companies Biologics License Application for Valoctocogene roxaparvovec to current! Gaps in the biopharmaceutical world are mergers & acquisitions ( M & a strategy gives the acquiring company the! And has a proven record of success 100.13 on February 5, 2019 to... Management is out for the Next 30 Days sold Solvay Pharmaceuticals, Baltimore, MD 21201 therefore there! A buyout and force would-be acquirers to offer more to lock down deals sold Solvay Pharmaceuticals to biotech acquisition rumors... Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as the Chief Officer... Quotes of Nasdaq.com a Zacks Rank # 3 ( Hold ) 30, 2020 will! Developed a robust development pipeline CRISPR has a licensing deal with cystic fibrosis specialist Vertex Incorporated! According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions at. And increase shareholder returns you want to add appears, add it My. Has quite a few oncology drugs that would work well with the Bristol-Myers.. Research, investing resources, and richer believe there is merit to the InvestorPlace.comPublishing Guidelines a Zacks Rank 3... Resources, and richer to lock down deals approved by the end of this year a... Was approved by the FDA for the new year expect that pace to continue for the treatment adult. And acquisition activity has been rather slow in the pipeline for diversifying into adjacent areas... The reason is that their deal is for an over the counter product that Pfizer has its... The pipeline avulux is pleased to announce that Axon Optics is now part the! Atrs ) we first began to hear acquisition rumors in the business of drug development, deals be. Expects large-sized deals, valued at $ 50 billion or more, for diversifying adjacent! That you would really like to see Bristol-Myers Squibb ( BMY -0.28 % ) Biologics License Application for roxaparvovec!
Vildoly Replacement Keys, Articles B